3b Blackbio Dx Ltd vs Avience Biomedicals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of 3B Blackbio DX Ltd is ₹ 1332 as of 23 Oct 15:30 . The P/E Ratio of 3B Blackbio DX Ltd changed from 1.9 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Avience Biomedicals Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of 3B Blackbio DX Ltd changed from ₹ 213.76 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Avience Biomedicals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of 3B Blackbio DX Ltd for the Jun '26 is ₹ 39.63 crore as compare to the Mar '26 revenue of ₹ 45.58 crore. This represent the decline of -13.05% The revenue of Avience Biomedicals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of 3B Blackbio DX Ltd for the Jun '26 is ₹ 14.67 crore as compare to the Mar '26 ebitda of ₹ 18.64 crore. This represent the decline of -21.3% The ebitda of Avience Biomedicals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of 3B Blackbio DX Ltd changed from ₹ 11.3 crore to ₹ 8.98 crore over 9 quarters. This represents a CAGR of -9.71% The net profit of Avience Biomedicals Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of 3B Blackbio DX Ltd changed from 391.92 % on March 2021 to 8.69 % on March 2026 . This represents a CAGR of -47.00% over 6 yearsThe Dividend Payout of Avience Biomedicals Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About 3B Blackbio DX Ltd

3D Blackbio DX Limited, formerly known as Kilpest India Limited was incorporated on May 25, 1972 as one of India's leading agro-business companies.
Thereafter, the holding Company, Kilpest India Limited got merged with 3B BlackBio Biotech India Limited and as per the Scheme of Amalgamation, the name of the Company was changed from Kilpest India Limited to 3B BlackBio DX Limited in August, 2023. The Company is a leading Indian biotech firm focused on molecular diagnostics (PCR kits, enzymes, reagents for diseases like cancer/ infectious diseases) under the 'TRUPCR' brand, alongside developing Next-Gen Sequencing (NGS) assays (TRUNGS) & Rapid Tests (TRURAPID), while continuing its traditional agrochemicals business (pesticides, bio-products), serving both labs and government sectors, driven by R&D for innovative solutions.

About Avience Biomedicals Ltd

Avience Biomedicals Limited was originally incorporated as Private Limited Company as 'Avience Biomedicals Private Limited' on December 23, 2019 with the Registrar of Companies, Delhi.
Later, Company's status got converted into a Public Limited Company, the name of the Company was changed to 'Avience Biomedicals Limited' and fresh Certificate of incorporation dated September 3, 2024, was issued by the Registrar of Companies, Delhi. Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India.
In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections. The Company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good-quality solutions.

FAQs for the comparison of 3B Blackbio DX Ltd and Avience Biomedicals Ltd

Which company has a larger market capitalization, 3B Blackbio DX Ltd or Avience Biomedicals Ltd?

Market cap of 3B Blackbio DX Ltd is 1,144 Cr while Market cap of Avience Biomedicals Ltd is 131 Cr

What are the key factors driving the stock performance of 3B Blackbio DX Ltd and Avience Biomedicals Ltd?

The stock performance of 3B Blackbio DX Ltd and Avience Biomedicals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for 3B Blackbio DX Ltd and Avience Biomedicals Ltd?

As of October 25, 2026, the 3B Blackbio DX Ltd stock price is INR ₹1332.95. On the other hand, Avience Biomedicals Ltd stock price is INR ₹240.0.

How do dividend payouts of 3B Blackbio DX Ltd and Avience Biomedicals Ltd compare?

To compare the dividend payouts of 3B Blackbio DX Ltd and Avience Biomedicals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.